Short Interest in Amyris Inc (AMRS) Decreases By 1.1%
Amyris Inc (NASDAQ:AMRS) saw a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 13,893,705 shares, a drop of 1.1% from the April 28th total of 14,041,318 shares. Based on an average daily volume of 6,883,547 shares, the days-to-cover ratio is currently 2.0 days.
Amyris (NASDAQ:AMRS) traded down 0.4053% during mid-day trading on Friday, reaching $0.2703. The company’s stock had a trading volume of 1,196,190 shares. The firm’s 50 day moving average is $0.44 and its 200-day moving average is $0.59. Amyris has a 12-month low of $0.24 and a 12-month high of $1.21. The company’s market cap is $75.23 million.
Amyris (NASDAQ:AMRS) last announced its quarterly earnings results on Monday, May 15th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.04. The company had revenue of $13 million for the quarter, compared to analysts’ expectations of $32.30 million. During the same period last year, the business posted ($0.17) earnings per share. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. Equities analysts anticipate that Amyris will post ($0.26) earnings per share for the current fiscal year.
In related news, major shareholder (Mauritius) Pte Ltd Maxwell sold 287,706 shares of Amyris stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $0.52, for a total transaction of $149,607.12. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Patrick Y. Yang bought 300,000 shares of the firm’s stock in a transaction that occurred on Friday, May 19th. The shares were acquired at an average cost of $0.29 per share, for a total transaction of $87,000.00. Following the purchase, the director now directly owns 153,000 shares in the company, valued at approximately $44,370. The disclosure for this purchase can be found here. Insiders have sold a total of 7,361,888 shares of company stock worth $3,877,084 in the last three months. 48.70% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in the company. Carl Domino Inc boosted its position in Amyris by 37.4% in the first quarter. Carl Domino Inc now owns 201,925 shares of the biotechnology company’s stock worth $107,000 after buying an additional 54,925 shares during the last quarter. Geode Capital Management LLC boosted its position in Amyris by 7.5% in the first quarter. Geode Capital Management LLC now owns 588,026 shares of the biotechnology company’s stock worth $311,000 after buying an additional 41,060 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Amyris by 42.4% in the first quarter. Vanguard Group Inc. now owns 4,419,446 shares of the biotechnology company’s stock worth $2,342,000 after buying an additional 1,315,809 shares during the last quarter. 30.40% of the stock is owned by hedge funds and other institutional investors.
Several analysts recently issued reports on AMRS shares. Zacks Investment Research downgraded Amyris from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 7th. HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Amyris in a research note on Tuesday.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc and related companies with MarketBeat.com's FREE daily email newsletter.